This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Proprietary portfolio of superior therapeutics for the treatment of diabetes and obesity
- Two clinical stage next-generation insulin candidates with compelling clinical superiority to best insulins available to patients today
- Positive negotiations with device companies to further develop and commercialise proprietary insulin products
- Novel technology platform for the oral delivery of peptides under development
Partnering with leading pharmaceutical and MedTech companies to develop enhanced therapeutic medicines
- One product now on the market that incorporates Arestat™ and generating royalties under worldwide license agreement
- Two additional products under license for further development and commercialisation
- Near term revenue-generation and significant future upside potential
Validated technology
- World-leading Arestat™ technology platform
- Extensive IP protection with >100 granted patents in US, Europe and key territories